- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | RFK Jr.-appointed panel recommends flu shots be free of contested preservative | ||
| Do | Vor, with new CEO, changes course to target autoimmune disease | ||
| Do | Acadia's 'very bullish' sales forecast restores some confidence on Wall Street | ||
| Do | Incyte replaces CEO Hoppenot with dealmaker Meury | ||
| Do | Recast CDC panel recommends new RSV antibody for infants | ||
| Do | CDC panel, newly remade by RFK Jr., questions vaccine evidence | ||
| Mi | Kymera adds Gilead as research partner, while advancing new candidate with Sanofi | ||
| Mi | FDA investigating Elevidys safety; Nektar shares spike on eczema data | ||
| Di | Lexeo to help launch spinout around RNA drugs for the heart | ||
| Di | Cassidy calls for delay to CDC vaccine meeting, challenging RFK Jr. | ||
| Di | New Amgen obesity drug data disappoint Wall Street | ||
| Di | Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug | ||
| Mo | Relentless innovation: Bold exploration in advancing therapeutic options for every patient, every discovery | ||
| Mo | Top drug official at FDA reportedly set to exit next month | ||
| Mo | Cidara stock soars as antiviral drug succeeds in flu study | ||
| Mo | Illumina to buy SomaLogic in deal worth up to $425M | ||
| Mo | Novo abruptly ends obesity drug deal with Hims | ||
| Mo | Compass' big psychedelic study doesn't impress investors | ||
| Mo | [Podcast] Trial Trailblazers: Behind clinical breakthroughs | ||
| Mo | The rise of GLP-1 drugs: Transforming weight loss treatment | ||
| 20.06. | Prothena to lay off majority of staff; Zealand shares obesity drug data | ||
| 20.06. | A longer 'winter': Public funding slowdown heightens pressure on biotech startups | ||
| 20.06. | Gene therapy faces fresh uncertainty as two more top FDA officials depart | ||
| 18.06. | FDA approves twice-yearly shot of Gilead drug for HIV prevention | ||
| 18.06. | Scholar Rock drug preserves muscle in obesity trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .